State of Wyoming Purchases 3,691 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

State of Wyoming grew its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 35.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,068 shares of the biopharmaceutical company’s stock after acquiring an additional 3,691 shares during the period. State of Wyoming’s holdings in Halozyme Therapeutics were worth $673,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Steamboat Capital Partners LLC raised its stake in shares of Halozyme Therapeutics by 43.6% during the fourth quarter. Steamboat Capital Partners LLC now owns 249,751 shares of the biopharmaceutical company’s stock valued at $11,941,000 after acquiring an additional 75,890 shares during the last quarter. Shay Capital LLC bought a new position in Halozyme Therapeutics in the fourth quarter worth about $215,000. Rafferty Asset Management LLC raised its stake in Halozyme Therapeutics by 16.4% in the fourth quarter. Rafferty Asset Management LLC now owns 219,392 shares of the biopharmaceutical company’s stock worth $10,489,000 after buying an additional 30,852 shares in the last quarter. Point72 Europe London LLP bought a new position in Halozyme Therapeutics in the fourth quarter worth about $1,403,000. Finally, ProShare Advisors LLC raised its stake in Halozyme Therapeutics by 28.8% in the fourth quarter. ProShare Advisors LLC now owns 47,114 shares of the biopharmaceutical company’s stock worth $2,253,000 after buying an additional 10,531 shares in the last quarter. 97.79% of the stock is owned by institutional investors.

Insider Activity

In other news, SVP Michael J. Labarre sold 1,697 shares of the stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total transaction of $98,901.16. Following the sale, the senior vice president now owns 173,756 shares in the company, valued at $10,126,499.68. This represents a 0.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Jeffrey William Henderson sold 4,497 shares of the stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $60.37, for a total transaction of $271,483.89. Following the sale, the director now owns 28,611 shares in the company, valued at approximately $1,727,246.07. The trade was a 13.58% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 21,697 shares of company stock worth $1,276,552 over the last 90 days. 2.40% of the stock is currently owned by insiders.

Halozyme Therapeutics Stock Up 6.3%

Shares of NASDAQ:HALO opened at $52.02 on Monday. The stock has a fifty day simple moving average of $60.69 and a two-hundred day simple moving average of $55.98. The stock has a market capitalization of $6.41 billion, a price-to-earnings ratio of 15.17, a PEG ratio of 0.42 and a beta of 1.26. Halozyme Therapeutics, Inc. has a 12-month low of $42.01 and a 12-month high of $70.51. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.98 by $0.13. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The business had revenue of $264.86 million during the quarter, compared to analysts’ expectations of $231.21 million. During the same quarter in the previous year, the business earned $0.79 earnings per share. The firm’s quarterly revenue was up 35.2% compared to the same quarter last year. On average, research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on HALO. Morgan Stanley downgraded shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $73.00 to $62.00 in a research note on Wednesday, May 14th. Leerink Partnrs downgraded shares of Halozyme Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, May 13th. JPMorgan Chase & Co. increased their price target on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a “neutral” rating in a research note on Monday, April 21st. Benchmark downgraded shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 7th. Finally, Wells Fargo & Company increased their price target on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an “equal weight” rating in a research note on Wednesday, May 7th. Two analysts have rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $61.90.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.